Pressemitteilung BoxID: 311232 (4SC AG)
  • 4SC AG
  • Fraunhoferstr. 22
  • 82152 Planegg-Martinsried
  • Ansprechpartner
  • Chad Rubin
  • +1 (646) 378-2947

4SC to host conference call on 10 May 2012 to present Q1 2012 financial results

(lifePR) (Planegg-Martinsried, Germany, ) 4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, will announce financial results of the 4SC Group for the first quarter of 2012 on 10 May 2012. On this day the Management Board of 4SC AG will host a conference call at 3pm CET (9am EST) to inform about the consolidated financial statements and important developments in the reporting period.

Participants can access the conference call under the following telephone numbers:

Date: 10 May 2012
Time: 3pm CET (9am EST)
Dial-in numbers:
+49 6103 485 3000 (Germany)
+44-207-153-2027 (UK)
+1-480-629-9725 (USA)
+49 6103 485 3000 (other countries)
Conference-ID: 4537583

Approximately two hours after the live presentation, an audio replay will be available at 4SC's website in the section "Investors / Events & Presentations / Conference calls & Webcasts".

Legal Note

This document may contain projections or estimates relating to plans and objectives relating to our future operations, products, or services; future financial results; or assumptions underlying or relating to any such statements; each of which constitutes a forward-looking statement subject to risks and uncertainties, many of which are beyond our control. Actual results could differ materially, depending on a number of factors.


The Group managed by 4SC AG (ISIN DE0005753818) discovers and develops targeted, small-molecule drugs for treating diseases with a high unmet medical need in various autoimmune and cancer indications. These drugs are intended to provide innovative treatment options that are more tolerable and efficacious than existing therapies, and provide a better quality of life. The Company's balanced pipeline comprises promising products that are in various stages of clinical development. 4SC's aim is to generate future growth and enhance its enterprise value by entering into partnerships with leading pharmaceutical companies. Founded in 1997, 4SC had 96 employees at the end of 2011. 4SC AG has been listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005.